Myriad Genetics Introduces Online Prenatal Genetic Testing Resource
SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing comprehensive information about ...
Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology
Study showed online screening tool and patient education improved genetic testing completion rateSALT LAKE CITY, Jan. 21, ...
Myriad Genetics stock hits 52-week low at $12.16 amid market challenges
Myriad Genetics , Inc. (NASDAQ:MYGN) stock has reached a new 52-week low, touching down at $12.16, as the company faces a challenging market environment. According to InvestingPro data, technical ...
Myriad Genetics announces hereditary cancer risk assessment study published
Myriad Genetics (MYGN) announced a study revealing that more patients completed hereditary cancer testing when they used an online screening ...
Leerink Partners Sticks to Their Hold Rating for Myriad Genetics (MYGN)
In a report released yesterday, Puneet Souda from Leerink Partners maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a ...
bovnews5d
Myriad Genetics Inc (MYGN) Posted -14.08% Profit Margin Last Year—Can It Hold Up?
Myriad Genetics Inc (MYGN) stock saw a decline, ending the day at $12.39 which represents a decrease of $-0.13 or -1.04% from the prior close of $12.52. The stock opened at $12.56 and touched a low of ...
Nasdaq6d
Lobbying Update: $290,000 of MYRIAD GENETICS INC. lobbying was just disclosed
$290,000 of MYRIAD GENETICS INC. lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "S.708 - legislation to require a ...
Medindia2d
Prostate Cancer: Are Genomic Tests the Future of Risk Assessment?
A systematic review highlights the potential of genomic tests in prostate cancer treatment decisions but calls for more data ...
CNN2d
Myriad Genetics, Inc.
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics ...
EurekAlert!3d
Gene classifier tests for prostate cancer may influence treatment decisions despite lack of evidence for long-term outcomes
A systematic review found that while genomic classifier (GC) tests may influence risk classifications or treatment decisions for patients with localized prostate cancer (PCa), there is a need for ...
Global Gastric Cancer Diagnostics Market Is Anticipated To Grow At A CAGR Of ~7% By 2030, Estimates Delveinsight
Gastric cancer diagnostics companies are Abbott, BD, Bio-Rad Laboratories, Roche, Siemens Healthineers, Thermo Fisher Scientific, Pillar Biosciences, ETC ...
News Medical on MSN3d
Exploring the use of genomic classifier tests in prostate cancer risk stratification
A systematic review found that while genomic classifier (GC) tests may influence risk classifications or treatment decisions for patients with localized prostate cancer (PCa), there is a need for ...